{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:24:03Z","timestamp":1791181443713,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,7,13]],"date-time":"2014-07-13T00:00:00Z","timestamp":1405209600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s00277-014-2151-8","type":"journal-article","created":{"date-parts":[[2014,7,12]],"date-time":"2014-07-12T01:58:20Z","timestamp":1405130300000},"page":"2029-2036","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia"],"prefix":"10.1007","volume":"93","author":[{"given":"Chih-Cheng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyh-Pyng","family":"Gau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ju","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Yu","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cih-En","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jrhau","family":"Lung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Sheng","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Wei","family":"Leu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hsien","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Der","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Huang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,13]]},"reference":[{"key":"2151_CR1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","volume":"22","author":"A Tefferi","year":"2008","unstructured":"Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22:14\u201322","journal-title":"Leukemia"},{"key":"2151_CR2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/sj.leu.2404946","volume":"22","author":"A Tefferi","year":"2008","unstructured":"Tefferi A (2008) The history of myeloproliferative disorders: before and after Dameshek. Leukemia 22:3\u201313","journal-title":"Leukemia"},{"key":"2151_CR3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott LM, Tong W, Levine RL et al (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356:459\u2013468","journal-title":"N Engl J Med"},{"key":"2151_CR4","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T et al (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3:e270","journal-title":"PLoS Med"},{"key":"2151_CR5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Vainchenker W (2011) Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 29:573\u2013582","journal-title":"J Clin Oncol"},{"key":"2151_CR6","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ et al (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369:2391\u20132405","journal-title":"N Engl J Med"},{"key":"2151_CR7","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379\u20132390","journal-title":"N Engl J Med"},{"key":"2151_CR8","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Ferretti V et al (2014) JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 123:1544\u20131551","journal-title":"Blood"},{"key":"2151_CR9","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","volume":"123","author":"G Rotunno","year":"2014","unstructured":"Rotunno G, Mannarelli C, Guglielmelli P et al (2014) Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 123:1552\u20131555","journal-title":"Blood"},{"key":"2151_CR10","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SHCE Swerdlow","year":"2008","unstructured":"Swerdlow SHCE, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, Lyon"},{"key":"2151_CR11","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","volume":"22","author":"G Barosi","year":"2008","unstructured":"Barosi G, Mesa RA, Thiele J et al (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 22:437\u2013438","journal-title":"Leukemia"},{"key":"2151_CR12","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G et al (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29:761\u2013770","journal-title":"J Clin Oncol"},{"key":"2151_CR13","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","volume":"110","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P et al (2007) Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110:840\u2013846","journal-title":"Blood"},{"key":"2151_CR14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.12075","volume":"160","author":"AJ Bench","year":"2013","unstructured":"Bench AJ, White HE, Foroni L et al (2013) Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. Br J Haematol 160:25\u201334","journal-title":"Br J Haematol"},{"key":"2151_CR15","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2006-08-039909","volume":"109","author":"N Kroger","year":"2007","unstructured":"Kroger N, Badbaran A, Holler E et al (2007) Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 109:1316\u20131321","journal-title":"Blood"},{"key":"2151_CR16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","volume":"112","author":"PA Beer","year":"2008","unstructured":"Beer PA, Campbell PJ, Scott LM et al (2008) MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 112:141\u2013149","journal-title":"Blood"},{"key":"2151_CR17","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/leu.2008.137","volume":"22","author":"R Chaligne","year":"2008","unstructured":"Chaligne R, Tonetti C, Besancenot R et al (2008) New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1\/S-phase transition. Leukemia 22:1557\u20131566","journal-title":"Leukemia"},{"key":"2151_CR18","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood-2008-10-183558","volume":"115","author":"C Pecquet","year":"2010","unstructured":"Pecquet C, Staerk J, Chaligne R et al (2010) Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. Blood 115:1037\u20131048","journal-title":"Blood"},{"key":"2151_CR19","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1182\/blood-2013-02-486050","volume":"121","author":"E Rumi","year":"2013","unstructured":"Rumi E, Pietra D, Guglielmelli P et al (2013) Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood 121:4388\u20134395","journal-title":"Blood"},{"key":"2151_CR20","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1007\/s00277-012-1502-6","volume":"91","author":"L Martinez-Aviles","year":"2012","unstructured":"Martinez-Aviles L, Alvarez-Larran A, Besses C et al (2012) Clinical significance of clonality assessment in JAK2V617F-negative essential thrombocythemia. Ann Hematol 91:1555\u20131562","journal-title":"Ann Hematol"},{"key":"2151_CR21","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","volume":"120","author":"F Passamonti","year":"2012","unstructured":"Passamonti F, Thiele J, Girodon F et al (2012) A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood 120:1197\u20131201","journal-title":"Blood"},{"key":"2151_CR22","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A et al (2012) Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 120:5128\u20135133, quiz 5252","journal-title":"Blood"},{"key":"2151_CR23","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","volume":"117","author":"A Carobbio","year":"2011","unstructured":"Carobbio A, Thiele J, Passamonti F et al (2011) Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 117:5857\u20135859","journal-title":"Blood"},{"key":"2151_CR24","doi-asserted-by":"crossref","unstructured":"Tefferi A, Lasho TL, Finke CM et al (2014) CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. doi: 10.1038\/leu.2014.3","DOI":"10.1038\/leu.2014.3"},{"key":"2151_CR25","doi-asserted-by":"crossref","unstructured":"Tefferi A, Wassie EA, Guglielmelli P et al (2014) Type 1 vs Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol doi: 10.1002\/ajh.23743","DOI":"10.1002\/ajh.23743"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2151-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-014-2151-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2151-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T09:49:53Z","timestamp":1559036993000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-014-2151-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,13]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["2151"],"URL":"https:\/\/doi.org\/10.1007\/s00277-014-2151-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,13]]}}}